MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term, appointed KPMG LLP as the Company’s auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries.
All candidates proposed for the position of director were elected in the following proportion:
| FOR | % FOR | ABSTENTION | % ABSTENTION | |
| Joseph Arena | 20,473,944 | 84.03% | 3,890,222 | 15.97% |
| Frank Holler | 19,089,786 | 78.35% | 5,274,380 | 21.65% |
| Paul Lévesque | 19,027,772 | 78.10% | 5,336,394 | 21.90% |
| Andrew Molson | 19,066,145 | 78.25% | 5,298,021 | 21.75% |
| Dawn Svoronos | 18,998,230 | 77.98% | 5,365,936 | 22.02% |
| Elina Tea | 19,163,502 | 78.65% | 5,200,664 | 21.35% |
| Dale Weil | 19,005,768 | 78.01% | 5,358,398 | 21.99% |
| Jordan Zwick | 19,618,725 | 80.52% | 4,745,441 | 19.48% |
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
514-336-7800
| Last Trade: | US$2.61 |
| Daily Change: | 0.02 0.77 |
| Daily Volume: | 242,822 |
| Market Cap: | US$120.010M |
April 09, 2025 April 08, 2025 March 12, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
